Spinal dementia: Don't miss it, it's treatable
Horst Urbach1,2, A El Rahal3,4, K Wolf3,4
1Department of Neuroradiology, Medical Center, Faculty of Medicine, University Medical Center Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany. horst.urbach@uniklinik-freiburg.de.
Neuroradiology
|July 10, 2024
Summary
Investigating rare spinal conditions causing cognitive decline revealed treatable causes in dementia patients. Early spinal imaging is crucial for diagnosing and treating conditions like spinal dementia.
Area of Science:
- Neurology
- Radiology
- Neurosurgery
Background:
- Approximately 5% of dementia cases stem from treatable causes.
- Rare spinal conditions can manifest as cognitive impairment.
- Investigating spinal-level treatable causes is essential for dementia management.
Purpose of the Study:
- To estimate the prevalence of rare spinal diseases causing cognitive decline.
- To highlight the link between spinal pathology and dementia.
- To introduce the concept of 'spinal dementia'.
Main Methods:
- Searched radiology information system using CT myelography and OPS code 3-241.
- Reviewed clinical charts of patients with spontaneous intracranial hypotension (SIH) and CSF leaks.
- Identified patients with cognitive decline, brain sagging, or infratentorial hemosiderosis.
Main Results:
- Five patients with frontotemporal brain sagging syndrome were identified, four with CSF venous fistulas that improved after treatment.
- Eleven patients presented with infratentorial hemosiderosis, hearing problems, and ataxia; at least two showed cognitive decline.
- Ten patients had thoracic dural tears, and one had a cervical dural tear; eight improved after surgery.
Conclusions:
- Spinal evaluation, particularly the thoracic spine, is mandatory for cognitively impaired patients with brain sagging or infratentorial changes.
- The term 'spinal dementia' is proposed to focus attention on spinal pathology.
- Dynamic digital subtraction and CT myelography are recommended for spinal evaluation in these cases.
Keywords:
DementiaFrontotemporal brain sagging syndromeInfratentorial hemosiderosis – CT myelographySpontaneous intracranial hypotensionMore Related Videos
Related Concept Videos
Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
Parkinson's Disease: Treatment
251
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
251
Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110
Myasthenia Gravis: Overview and Treatment
1.3K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.3K
Parkinson's Disease: Overview
522
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
522
Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461


